Evaluation of arecoline hydrobromide toxicity after a 14-day repeated oral administration in Wistar rats.

A subchronic toxicity test was conducted in rats on the basis of a previous acute toxicity test to evaluate the safety of arecoline hydrobromide (Ah), to systematically study its pharmacological effects and to provide experimental support for a safe clinical dose. Eighty rats were randomly divided i...

Full description

Bibliographic Details
Main Authors: Xiaojuan Wei, Jiyu Zhang, Jianrong Niu, Xuzheng Zhou, Jianyong Li, Bing Li
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4399984?pdf=render
id doaj-8cc1a6d67af845c89e109e8537b0961f
record_format Article
spelling doaj-8cc1a6d67af845c89e109e8537b0961f2020-11-25T01:03:35ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01104e012016510.1371/journal.pone.0120165Evaluation of arecoline hydrobromide toxicity after a 14-day repeated oral administration in Wistar rats.Xiaojuan WeiJiyu ZhangJianrong NiuXuzheng ZhouJianyong LiBing LiA subchronic toxicity test was conducted in rats on the basis of a previous acute toxicity test to evaluate the safety of arecoline hydrobromide (Ah), to systematically study its pharmacological effects and to provide experimental support for a safe clinical dose. Eighty rats were randomly divided into four groups: a high-dose group (1000 mg/kg), medium-dose group (200 mg/kg), low-dose group (100mg/kg) and blank control group. The doses were administered daily via gastric lavage for 14 consecutive days. There were no significant differences in the low-dose Ah group compared to the control group (P>0.05) with regard to body weight, organ coefficients, hematological parameters and histopathological changes. The high-dose of Ah influenced some of these parameters, which requires further study. The results of this study indicated that a long-term, continuous high dose of Ah was toxic. However, it is safe to use Ah according to the clinically recommended dosing parameters. The level of Ah at which no adverse effects were observed was 100 mg/kg/day under the present study conditions.http://europepmc.org/articles/PMC4399984?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Xiaojuan Wei
Jiyu Zhang
Jianrong Niu
Xuzheng Zhou
Jianyong Li
Bing Li
spellingShingle Xiaojuan Wei
Jiyu Zhang
Jianrong Niu
Xuzheng Zhou
Jianyong Li
Bing Li
Evaluation of arecoline hydrobromide toxicity after a 14-day repeated oral administration in Wistar rats.
PLoS ONE
author_facet Xiaojuan Wei
Jiyu Zhang
Jianrong Niu
Xuzheng Zhou
Jianyong Li
Bing Li
author_sort Xiaojuan Wei
title Evaluation of arecoline hydrobromide toxicity after a 14-day repeated oral administration in Wistar rats.
title_short Evaluation of arecoline hydrobromide toxicity after a 14-day repeated oral administration in Wistar rats.
title_full Evaluation of arecoline hydrobromide toxicity after a 14-day repeated oral administration in Wistar rats.
title_fullStr Evaluation of arecoline hydrobromide toxicity after a 14-day repeated oral administration in Wistar rats.
title_full_unstemmed Evaluation of arecoline hydrobromide toxicity after a 14-day repeated oral administration in Wistar rats.
title_sort evaluation of arecoline hydrobromide toxicity after a 14-day repeated oral administration in wistar rats.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description A subchronic toxicity test was conducted in rats on the basis of a previous acute toxicity test to evaluate the safety of arecoline hydrobromide (Ah), to systematically study its pharmacological effects and to provide experimental support for a safe clinical dose. Eighty rats were randomly divided into four groups: a high-dose group (1000 mg/kg), medium-dose group (200 mg/kg), low-dose group (100mg/kg) and blank control group. The doses were administered daily via gastric lavage for 14 consecutive days. There were no significant differences in the low-dose Ah group compared to the control group (P>0.05) with regard to body weight, organ coefficients, hematological parameters and histopathological changes. The high-dose of Ah influenced some of these parameters, which requires further study. The results of this study indicated that a long-term, continuous high dose of Ah was toxic. However, it is safe to use Ah according to the clinically recommended dosing parameters. The level of Ah at which no adverse effects were observed was 100 mg/kg/day under the present study conditions.
url http://europepmc.org/articles/PMC4399984?pdf=render
work_keys_str_mv AT xiaojuanwei evaluationofarecolinehydrobromidetoxicityaftera14dayrepeatedoraladministrationinwistarrats
AT jiyuzhang evaluationofarecolinehydrobromidetoxicityaftera14dayrepeatedoraladministrationinwistarrats
AT jianrongniu evaluationofarecolinehydrobromidetoxicityaftera14dayrepeatedoraladministrationinwistarrats
AT xuzhengzhou evaluationofarecolinehydrobromidetoxicityaftera14dayrepeatedoraladministrationinwistarrats
AT jianyongli evaluationofarecolinehydrobromidetoxicityaftera14dayrepeatedoraladministrationinwistarrats
AT bingli evaluationofarecolinehydrobromidetoxicityaftera14dayrepeatedoraladministrationinwistarrats
_version_ 1725200543577538560